Sökning: WFRF:(Diener Hans Christoph) >
Changes in Renal Fu...
Changes in Renal Function in Patients With Atrial Fibrillation An Analysis From the RE-LY Trial
-
Boehm, Michael (författare)
-
Ezekowitz, Michael D. (författare)
-
Connolly, Stuart J. (författare)
-
visa fler...
-
Eikelboom, John W. (författare)
-
Hohnloser, Stefan H. (författare)
-
Reilly, Paul A. (författare)
-
Schumacher, Helmut (författare)
-
Brueckmann, Martina (författare)
-
Schirmer, Stephan H. (författare)
-
Kratz, Mario T. (författare)
-
Yusuf, Salim (författare)
-
Diener, Hans-Christoph (författare)
-
- Hijazi, Ziad (författare)
- Uppsala universitet,Uppsala kliniska forskningscentrum (UCR),Kardiologi
-
- Wallentin, Lars (författare)
- Uppsala universitet,Uppsala kliniska forskningscentrum (UCR),Kardiologi
-
visa färre...
-
(creator_code:org_t)
- Elsevier BV, 2015
- 2015
- Engelska.
-
Ingår i: Journal of the American College of Cardiology. - : Elsevier BV. - 0735-1097 .- 1558-3597. ; 65:23, s. 2481-2493
- Relaterad länk:
-
https://doi.org/10.1...
-
visa fler...
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- BACKGROUND Vitamin K-dependent factors protect against vascular and renovascular calcification, and vitamin K antagonists may be associated with a decreased glomerular filtration rate (GFR). OBJECTIVES This study analyzed changes in GFR during long-term treatment with warfarin or dabigatran etexilate (DE) in patients enrolled in the RE-LY (Randomized Evaluation of Long Term Anticoagulation Therapy) trial. METHODS Of the 18,113 patients in the RE-LY study randomized to receive DE (110 mg or 150 mg twice daily) or warfarin, 16,490 patients with atrial fibrillation had creatinine values measured at baseline and at least 1 follow-up visit. Changes in GFR for up to 30 months were evaluated. RESULTS GFR declined in all treatment groups. After an average of 30 months, the mean +/- SE decline in GFR was significantly greater with warfarin (-3.68 +/- 0.24 ml/min) compared with DE 110 mg (-2.57 +/- 0.24 ml/min; p = 0.0009 vs. warfarin) and DE 150 mg (-2.46 +/- 0.23 ml/min; p = 0.0002 vs. warfarin). A decrease in GFR >25% was less likely with DE 110 mg (hazard ratio: 0.81 [95% confidence interval: 0.69 to 0.96]; p = 0.017) or DE 150 mg (hazard ratio: 0.79 [95% confidence interval: 0.68 to 0.93]; p = 0.0056) than with warfarin in the observation period >18 months. Patients with poor international normalized ratio control (i.e., time in therapeutic range <65%) exhibited a faster decline in GFR. A more pronounced decline in GFR was associated with previous warfarin use and with the presence of diabetes. CONCLUSIONS Patients with atrial fibrillation receiving oral anticoagulation exhibited a decline in renal function that was greater in those taking warfarin versus DE, and it was amplified by diabetes and previous vitamin K antagonist use.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Kardiologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cardiac and Cardiovascular Systems (hsv//eng)
Nyckelord
- anticoagulation
- atrial fibrillation
- renal function
- thrombin inhibition
- vitamin K antagonist
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Boehm, Michael
-
Ezekowitz, Micha ...
-
Connolly, Stuart ...
-
Eikelboom, John ...
-
Hohnloser, Stefa ...
-
Reilly, Paul A.
-
visa fler...
-
Schumacher, Helm ...
-
Brueckmann, Mart ...
-
Schirmer, Stepha ...
-
Kratz, Mario T.
-
Yusuf, Salim
-
Diener, Hans-Chr ...
-
Hijazi, Ziad
-
Wallentin, Lars
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Kardiologi
- Artiklar i publikationen
-
Journal of the A ...
- Av lärosätet
-
Uppsala universitet